Limited systemic sclerosis

Summary

Limited systemic sclerosis (MONDO:0016359) is a disease. A subtype of systemic sclerosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		200	Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	limited systemic sclerosis
Mondo ID	MONDO:0016359
Orphanet	220407
ICD-11	187455179
NCIT	C116789
SNOMED CT	128461001
UMLS	C1290138
MedGen	220934
GARD	0009749
Is cancer (heuristic)	no

Also known as: progressive systemic sclerosis sine scleroderma · Scleroderma, sine · SSC without skin involvement · systemic sclerosis sine scleroderma · systemic sclerosis without skin involvement

Disease family

This is a subtype of systemic sclerosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › systemic sclerosis › limited systemic sclerosis

Related subtypes (5): pulmonary systemic sclerosis, diffuse scleroderma, scleroderma, familial progressive, diffuse cutaneous systemic sclerosis, limited cutaneous systemic sclerosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.